Afirmelle Kit
Product Images NDC 65862-849
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Afirmelle (NDC 65862-849). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure I: Mean (se) Levonorgestrel And Ethinyl Estradiol Serum Concentrations In 22 Subjects Receiving Levonorgestrel And Ethinyl Estradiol (100 Mcg Levonorgestrel And 20 Mcg Ethinyl Estradiol) (Levo Ethi Fig1)
Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral-contraceptive Use (Levo Ethi Fig2)
Figure Iii: Risk Of Breast Cancer With Combined Oral Contraceptive Use (Levo Ethi Fig3)
Figure 4 (Levo Ethi Fig4)
Figure 5 (Levo Ethi Fig5)
Figure 6 (Levo Ethi Fig6)
Figure 7 (Levo Ethi Fig7)
Package Label-principal Display Panel (0.1 mg/0.02 mg (28 Tablets Pouch))
Package Label-principal Display Panel (0.1 mg/0.02 mg (Contains 6 Pouches of 28 Tablets Each))
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.